Pluristem Therapeutics Inc (PSTI)

[lbman]

Equities research analysts at Needham & Company initiated coverage on shares of Pluristem Therapeutics (NASDAQ: PSTI) in a research note to investors on Monday. The analysts set a “buy” rating and a $5.00 price target on the stock.

Separately, analysts at WBB Securities initiated coverage on shares of Pluristem Therapeutics in a research note to investors on Tuesday, March 1st. They set a “buy” rating and a $4.00 price target on the stock. Also, analysts at National Securities initiated coverage on shares of Pluristem Therapeutics in a research note to investors on Monday, January 10th. They set a “buy” rating on the stock.

Shares of Pluristem Therapeutics opened at 2.96 on Tuesday. Pluristem Therapeutics has a 52 week low of $0.94 and a 52 week high of $4.38. The stock’s 50-day moving average is $2.51 and its 200-day moving average is $1.99. The company has a market cap of $122.3 million.

Pluristem Therapeutics Inc. (Pluristem) is a bio-therapeutics company engaged in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from human placenta, a non-controversial, non-embryonic, adult stromal cell source. The placental adherent stromal cells (ASCs) are grown in the Company’s PluriX three-dimensional (3-D) bioreactor, which imitates the natural microstructure of the body. It is focusing on clinical indication that the route of administration is intramuscular. This route of administration applicable for several different indications, such as Peripheral artery disease (PAD), Critical limb ischemia (CLI), intermittent claudication, neuropathic pain, wound healing and orthopedic injuries.



http://www.americanbankingnews.com/2011/04/05/needham-company-analysts-begin-coverage-on-pluristem-therapeutics-psti/